FLX475

Drug Hunter's 2024 highlights include popular resources, molecules of the month, drug discovery trends, and key conferences. Notable developments: NVP-EDI048 for Cryptosporidium, RPT193's halted development, acoramidis FDA approval for ATTR-CM, rezatapopt's promise in oncology, TYRA-300's pediatric potential, and industry collaborations targeting neurodegenerative diseases and obesity.

RAPT Therapeutics halted its zelnecirnon clinical program for inflammatory disorders after FDA feedback, following a serious adverse event leading to a liver transplant. The decision caused a 48% drop in shares. RAPT plans to focus on next-gen CCR4 compounds, with tivumecirnon remaining its sole clinical-stage asset.

The FDA issued a clinical hold on zelnecirnon trials due to a patient's liver failure, potentially linked to the drug. Dosing and new enrollments are paused, except for RAPT's tivumecirnon oncology trial. No liver toxicity was found in other participants or nonclinical studies. RAPT investigates the case, emphasizing patient safety and FDA collaboration.

Bank of America's Savita Subramanian advises against Warren Buffet's index fund strategy, recommending small-cap value stocks instead for higher returns. Highlighted stocks include RAPT Therapeutics and Kura Oncology, both with strong buy ratings and significant upside potential, focusing on innovative treatments in biotech.